Chris Garabedian discusses some of Xontogeny’s recent activity. Xontogeny is a biotech aggregator which supports the accelerated development of life science technologies in the pursuit of helping patients with serious diseases.
Dr. John Maraganore, CEO of Alnylam discusses Henri A. Termeer Tribute Committee.
Chris Garabedian discusses his company Xontogeny, a biotech aggregator which supports the accelerated development of life science technologies in the pursuit of helping patients with serious diseases.
Lorenzo Pellegrini, PhD, Chief Executive Officer of Palladio Biosciences, discusses the company’s lead clinical therapy lixivaptan, a selective vasopressin V2 receptor antagonist.
Rob Neville of Savara Pharmaceuticals provides an overview of his company’s Molgradex (for PAP and NTM lung infection) and AeroVanc (an inhaled formulation of vancomycin, for the treatment of persistent methicillin-resistant Staphylococcus aureus, or MRSA, lung infection in cystic fibrosis)
Dr. John Maraganore, CEO of Alnylam highlights the importance of diversity. Maraganore has led a career pursuing therapies to address unmet medical needs. He is helping lead the development of RNAi therapeutics which aim to address genetic medicines, cardio-metabolic diseases and hepatic infectious diseases.